Preliminary Results of 9MW2821 Targeting Nectin-4ADC in Advanced Solid Tumor Patients: Report from ESMO 2023

The preliminary results of the phase I/II study evaluating the safety, tolerability, and preliminary efficacy of 9MW2821, a Nectin-4-targeting antibody-drug conjugate (ADC)

Related Keywords

Spain ,Madrid ,Jian Zhang ,European Society For Medical Oncology ,Fudan University Cancer Hospital ,Professor Jian Zhang ,European Society ,Medical Oncology ,